![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Abraham S.C., Cruz-Correa M., Lee L.A., Yardley J.H. and Wu T.T. (1999) Alendronate-associated esophageal injury: pathologic and endoscopic features. Modern Pathology, 12, 1152–1157.
- Arboleya L.R., Morales A. and Fiter J. (2000) Effect of alendronate on bone mineral density and incidence of fractures in postmenopausal women with osteoporosis. A meta-analysis of published studies. Medicina Clinica, 114 (Suppl. 2), 79–84.
- Castelo-Branco C. (1998) Management of osteoporosis. An overview. Drugs and Aging, 12 (Suppl. 1), 25–32.
- Felsenberg D., Alenfeld F., Bock O., Hammermeister C. and Gowan W. (1998) Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT Study Group. Fosamax International Trial. Maturitas, 31, 35–44.
- Firschein H.E. and Shill J.P. (1966) The determination of total hydroxiproline in urine and bone extracts. Analytical Biochemistry, 14, 296–304.
- Freise J. and Kohler S. (1999) Peppermint oil-caraway oil fixed combination in non-ulcer dyspepsia-comparison of the effects of enteric preparations. Pharmazie, 54, 210–215.
- Gertz B.J., Holland S.D., Kline W.F., Matuszewski B.K. and Porras A.G. (1993) Clinical pharmacology of alendronate sodium. Osteoporosis International, Suppl. 3, S13–516.
- Greenspan S.L., Rosen H.N. and Parker R.A. (2000) Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. Journal of Clinical Endocrinology and Metabolism, 85, 3537–3540.
- Kyd P.A., De Vooght K., Kerkhoff F., Thomas E. and Fairney A. (1999) Clinical usefulness of biochemical resorption markers in osteoporosis. Annals of Clinical Biochemistry, 36, 483–491.
- Miller P.D., Woodson G., Licata A.A., Ettinger M.P., Mako B., Smith ME., Wang L., Yates S.J., Melton M.E. and Palmisano J.J. (2000) Rechallenge of patients who had dis-continued alendronate therapy because of upper gastro-intestinal symptoms. Clinical Therapeutics, 22, 1433–1442.
- Pols HA., Felsenberg D., Hanley D.A., Stepan J., Munoz-Torres M., Wilkin T.J., Qin-Sheng G., Galich A.M., Vandormaal K., Yates A.J. and Stych B. (1999) Multi-national, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporosis International, 9, 461–468.
- Ravn P., Hosking D., Thompson D., Cizza G., Wasnich RD., McClung M., Yates A.J., Bjarnason N.H. and Christiansen C. (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. Journal of Clinical Endocrinology and Metabolism, 84, 2363–2368.
- Rossini M., Gatti D., Girardello S., Braga V., James G. and Adami S. (2000) Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis. Bone, 27, 119–122.
- Schnitzer T., Bone HG., Crepaldi G., Adami S., McClung M., Kiel D., Felsenberg D., Recker R.R., Tonino R.P. and Roux C. (2000) Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging, 12, 1–12.
- United States Pharmacopeia (USP) (2000) Edition 24 (U5P24). Rockville, United States Pharmacopeial Convention Inc. 1944–1951.
- Ventura V., Mauloni M., Mura M., Paltrinieri F. and de Aloysio D. (1996) Ultrasound velocity changes at the proximal phalanxes of the hand in pre-, pen- and postmenopausal women. Osteoporosis International, 6, 368–375.
- World Medical Association (1997) Declaration of Helsinki. Journal of the American Medical Association, 277, 925–926.